Index of Contributors

Amenta, F., 33–44
Anisimov, V. N., 161–169
Antognini, A., 72–78
Arbel, I., 79–88

Barbagallo, M., 253–269
Barbagallo, Sangiorgi, G., 253–269
Bărbat, I. M., 315–331
Bartsch, R., 122–128
Basso, A., 72–78
Bellani, M., 307–314
Benešová, O., 89–101
Bergamini, E., 174–179
Bertoni-Freddari, C., 137–149
Bongrani, S., 33–44
Borchelt, M., 270–281
Botezat-Antonescu, L., 315–331
Bresnahan, E. L., 16–32
Brezis, M., 209–212, 213–215
Brugo, M. A., 198–208

Cadel, S., 33–44
Cantatore, P., 150–160
Carrillo, M. C., 60–71
Casoli, T., 137–149
Cavallini, G., 174–179
Colombo, D., 307–314
Colombo, M., 307–314
Conte Camerino, D., 180–188, 244–252

Dachir, S., 79–88
Daddabbo, L., 150–160
Daghetta, L., 307–314
Dajkó, G., 115–121
Davis, L. J., 299–306
Della Croce, F., 307–314
De Luca, A., 180–188
De Tata, V., 174–179
Di Stefano, G., 307–314
Docherty, J. R., 282–292
Dostál, M., 89–101
Driver, C. J. E., 189–197
Duraković, Z., 293–298

Fabris, N., 307–314
Fattoretti, P., 137–149
Fracasso, F., 150–160

Gadaleta, M. N., 150–160, 233–243
Gandolfi, M. C., 307–314
Giordano, M., 253–269
Gori, Z., 174–179
Goyal, R., 170–173
Grasso, G., 198–208, 226–232
Greenfeld, Z., 209–212, 213–215
Greig, N. H., 16–32

Harman, D., ix, 1–15
Head, E., 45–59
Horgas, A. L., 270–281

Iijimi, S., 16–32
Ingram, D. K., 16–32
Ivy, G. O., 45–59, 60–71

Kadar, T., 79–88
Kanai, S., 60–71
Kitani, K., ix, 60–71
Klaschka, J., 89–101
Kmiec, Z., 216–225
Korn, E., 122–128
Krištofiková, Z., 89–101
Kuo, H., 16–32

Levy, A., 79–88
Licastro, F., 299–306
Loguercio Polosa, P., 150–160
London, E. D., 16–32

Mallamaci, R., 244–252
Masiello, P., 174–179
Massai, L., 226–232
Mateescu, R., 332–342
Măties, R., 332–342
Meichelböck, A., 122–128
Meier-Ruge, W., 137–149
Meli, M., 253–269
Migliaccio, P., 198–208
Migliorino, M., 307–314
Mihalas, G., 332–342
Mihalas, I. G., 332–342
Milgram, N. W., 45–59
Morini, M. C., 299–306
Müller, W. E., 122–128
Murphy, M. P., 45–59
Muscettola, M., 198–208, 226–232
Muzzioli, M., 307–314

Nagy, K., 115–121
Novelli, M., 174–179

Olivieri, C., 150–160

Panzarasa, R., 253–269
Paradies, G., 233–243

Peleg, I., 209–212
Pénzes, I., 129–136
Petrosillo, G., 233–243
Petruzzella, V., 150–160
Piantanelli, L., 72–78
Pierno, S., 180–188
Pisanty, S., 209–212
Popa, R., 332–342
Predescu, V., 315–331
Provinciali, M., 307–314

Quagliariello, E., 233–243

Rathaus, M., 213–215
Reid, C., 45–59
Ricci, A., 33–44
Rick, J. T., 45–59
Riga, S., 315–331
Riga, D., 315–331
Rosen, S., 209–212
Rossolini, G., 72–78
Rostock, A., 122–128
Ruggiero, F. M., 233–243

Sármány, J., 129–136
Scarpazza, P., 307–314
Schneider, F., 332–342
Sharma, S. P., 170–173
Singh, B., 170–173
Spagna, C., 137–149
Spangler, E. L., 16–32
Stefanigă, P., 332–342
Stoll, S., 122–128

Tanganelli, C., 198–208, 226–232
Tarnawa, I., 129–136
Tejkalová, H., 89–101
Testa, R., 72–78
Tóth, S., 129–136
Tricarico, D., 244–252
Turlea, J., 315–331

Uray, I., 115–121

Valsecchi, B., 33–44
Viticchi, C., 72–78
Vogrig, D. J., 189–197

Wagner, R., 244–252

Zaia, A., 72–78
Zeng, Y.-C., 33–44
Zs.-Nagy, I., ix, 102–114, 115–121

Subject Index

Acetyl-L-carnitine (AC)
  effect of, on cytochrome oxidase activity, 234
  mitDNA transcription and 150
Active avoidance learning, α-lipoic acid treatment and, 123
Adenosine diphosphate (ADP), rat heart mitochondria and, 237
Adenosine triphosphate (ATP), Hydergine increases stores of, 145
Adenosine triphosphate–sensitive potassium (K_{ATP}^+) channels, cysteine restores activity of, 244
α-Adrenoceptors, vasoconstrictor responses mediated by, 282
Adverse drug reactions (ADR), screening elderly population for, 270
Age
  agonist potency and, 289
  effects of, on performance, 18
  glutamate antagonistic effect of GYKI 52466 and, 129
Aging
  cardiovascular system and, 282
  corticosterone treatment and, 85
  cytochrome *c* oxydase activity and, 234
  energetic deficit associated with, 155
  free-radical theory of, 3
  immune system and, 167
  impaired metabolism cause or consequence of, 143
  ionic conductances during, 181
  modified life span and, 74
  organic mental disorders and, 315
  phosponoformic acid and, 195
  postponement of, three approaches to, 166
  progeroid syndromes a model of, 299
  rate of, geroprotectors and, 165
  synaptic mitochondria during, 137
Aging process, 3
Alcohol consumption, human, 162
Alzheimer's disease (AD), α-lipoic acid and, 126
Antagonic-stress, 315
  superiority of, 332
Antibody response, impaired, 307
Antioxidant enzyme activities, (−)deprenyl and, 68
Antioxidants
  life span and, 6
  onset of aging slowed by, 166
Astrocyte profiles, density of, 35
Atherosclerosis, molecular oxygen and, 8

Bacillus subtilis spores, restorative effect of, 198
BCE-001
  available data on, 102
  free radical scavenger properties of, 115
Benzodiazepine receptors, diazepam and, 98
Berlin Aging Study (BASE), 270
1,3-Bis(dimethylamino)-2-propanol (BIDIP), 105
  BCE-001 containing, 115
Blood brain barrier, antagonists and, 129
Blood chemistry, L-deprenyl treatment and, 46
Blood urea nitrogen (BUN), renal failure and, 277
Body weight
  constant light regime and, 168
  corticosterone treatment and, 81
  L-deprenyl treatment and, 46
Bovine serum albumin (BSA)
  BCE-001 and, 106
  exposure of, to oxygen radicals, 115
  immunization by, 91
Brain
  biochemical analysis of, 91
  senescence of, in Down's syndrome, 301
Brain cortex, effects of BCE-001 on, 109
Butylated hydroxytoluene (BHT)
  free-radical reaction inhibition by, 5
  tumors induced by, 166

Caloric restriction
  life span and, 6
  natural aging and, 77
  strong, 167
Cancer
  free radical formation and, 8
  geroprotectors and, 164
Carboxyatractiloside (CAT), adenosine diphosphate carrier activity titrated with, 237
Cardiolipin, cytochrome oxidase, and 233
Catalase (CAT)
  (−)deprenyl and, 62
  hydrogen peroxide eliminated by, 170
Centrophenoxine (CPH), 103
  free radical scavenger properties of, 115
Cerebral ischemic attacks, α-glycerophosphocholine in mental recovery of, 253
Chemiluminescence (CL), 303
Chloride channel conductance, aging rat skeletal muscle and, 180

2-*p*-Chlorophenoxy propionic acid (CPP), chloride channel conductance and, 182
p-Chlorophenoxyacetic acid (PCPA), 103
Choline synthesis cycle, 103
Cholineacetyltransferase (CAT), Hydergine increases activity of, 145
Clock, biological, mitochondria as, 155
Cloramphenicol (CAP), protein synthesis performed in presence of, 157
Cognitive functions, corticosterone treatment and, 85
Collagen types I and III, levels of, in rat kidney, 210
Concanavalin A (ConA), IFN-γ production and, 198, 277
Congestive heart failure, etiology of, 294
Corticosterone (COR), mild stress and, 79
Crichton Rating Scale (CRS), 256
Cu/Zn superoxide dismutase, 8
Cyclic adenosine monophosphate (cAMP)
  Hydergine and, 145
  rat hepatocytes protected by, 223
d-Cycloserine, memory performance in rats and, 23
Cyclosporin (CsA), rat kidney treated with, 209
Cysteine, activity of (K_{ATP}^+) channels restored by, 244
Cytochrome *c* oxidase (COX)
  cardiolipin and, 233
  kinetic studies of, 234
  muscle fibers and, 155

Death
  cause of, 164
  chance of, 1
Defecation, rate of, 92
Delayed matching or nonmatching to sample (DNMS), 55
(−)Deprenyl, life span and, 60
L-Deprenyl (DPR)
  aging brain and, 33
  effects of, on manifestations of aging in rat and dog, 45
  mouse survival kinetics and, 72
  nerve cell profiles and, 37
Deterioration index, 336
Diazepam, early postnatal treatment with, 89
Dideoxyadenosine (ddI), reverse transcriptase experiments and, 190
Dietary protein, life span and, 6
Digoxin, high plasma, 293
L-Dihydroxyphenilalanine (DOPA), mice treated with, 164
5,5-Dimethyl-1-pyrroline-*N*-oxide (DMPO), spin trapping with, 117
Dimethylaminoacetamide (DMA), α-lipoic acid in, 123
Dimethylaminoethanol (DMEA), 103
  free radical scavenger properties of, 115
2,4-Dinitrophenylhydrazine (DNPH), protein carbonyl content and, 115
Diphenyl-hexatriene (DPH) labeling, BCE-001 treatment and, 108
Disease, free-radical, 7
Diuretics, 271, 277, 279
Dizocilpine (DIZO), NMDA receptor complex and, 22
Dog, L-deprenyl treatment of, 54
Down's syndrome (DS), immune defects associated with, 300

Electrocardiogram (ECG), digoxin level and, 293
Electrolyte balance, adverse drug reactions in, 274
Electron spin resonance (ESR) spectroscopy
  BCE-001 and, 107, 118
  centrophenoxine and, 118
Endocrine system, senescence of, in Down's syndrome, 301
Epithalamin, long-term administration of, 167
Estrous cycle
  constant light regime and, 168
  diazepam treatment and, 94
Ethoxyquin, 6
2-Ethyl-6-methyl-3-oxypyridine, antigonadotropic activity of, 166
Ethylendiaminotetraacetate (EDTA-Na_2), geroprotector activity of, 166

Fat, limitation of, 167
Fluid homeostasis, adverse drug reactions in, 274
Fluorescence recovery after photobleaching (FRAP) technique, 109
Fly
  Drosophila, genetic and environmental factors affecting, 163
  Drosophila melanogaster mutant strain *white,* phosponoformic acid treatment of, 190
  Drosophila melanogaster wild-type strain Canton-S, phosponoformic acid treatment of, 190
Free radical attacks, Alzheimer's dementia and, 338
Free radical scavenger
  α-lipoic acid as, 122
  centrophenoxine and BCE-001, 115
Free radical theory of aging, 3
  old, simplistic approach vs., 111

Free radicals
life span and, 166
mitochondrial population and, 144

Galactosamine (GalN), rats incubated with, 216
Ganglion, visceral, 133
Gerbil, radial-arm maze test of, 4
Geriforte, evaluation of, 170
German Physician's Desk Reference, 273, 279
Gerontology, paradox of, 163
Gerontopsychiatry, antagonic-stress in, 315, 332
Geroprotectors, cancer and, 164
Glial fibrillary acidic protein (GFAP), 34
Glial fibrillary acidic protein–immunoreactive astroglial cells, 42
Global Deterioration Score (GDS), 258
Glomerular filtration rate (GFR), 213
Glucose, plasma, vanadyl sulfate and, 175
L-Glutamate, sensitivity of gastropoda neurons to, 130
Glutamate receptors, non-NMDA type, 129
Glutathione peroxidase (GPx)
(−)deprenyl and, 62
hydrogen peroxide eliminated by, 170
α-Glycerophosphocholine (α-GPC), cerebral ischemic attacks and, 253
Glycogen, muscle, vanadyl sulfate and, 174
Golgi cells, 138
Gompertz curve, 166
Granulocyte activity in Down's syndrome, 303
Growth hormone (GH), reduced level of, 180
Gut-associated lymphoid tissue (GALT), IFN production and, 203
GYKI 52466, glutamate antagonistic effect of, 129

Hamilton Anxiety Scale (HAS), 317
Hamilton Depression Scale (HDS), 317
Hepatocyte membrane proteins, lateral mobility of, effect of BCE-001 on, 109
Hepatocytes, isolated
effects of galactosamine on, 218
effects of prostaglandins on, 219
Hippocampus
CA1 and CA3 fields of, 36
CA1 and CA4 fields of, 87
Human
adverse drug reactions and, 270
BCE-001 treatment of, 111
cancer in, 162
cytochrome *c* oxidase activity in, 155
digoxin treatment of, 293
geroprotectors and, 161
α-glycerophosphocholine treatment of, 253
Hydergine treatment of, 146
influenza vaccine for, 307
LINE-1 and *alu* elements in, 189
mitDNA in, 150, 157
prostaglandin E_1 treatment of, 216
strong caloric restriction in, 167
vasoconstrictor responses in, 282
Hydergine, nerve cell metabolism improved by, 137
8-Hydroxydeoxyguanosine (8-OH-dG), oxidative mitDNA damage measured as, 156
5-Hydroxytryptamine (5-HT), vasoconstrictor responses mediated by, 282
Hypertension, essential, 9
Hypotension, postural, 289
Hypothesis
cholinergic, 19
dysdifferentiation, of aging and cancer (DHAC), 102
glucocorticoid, of brain aging, 79
glucocorticoid cascade, 79
glutamate, 21
membrane, of aging (MHA), 102, 122
power failure, 143

Immune system, aging and, 167
Influenza vaccine, impaired antibody response to, 307
Institutionalized elderly, influenza vaccine and, 307
Insulin, plasma, vanadyl sulfate and, 175
Insulin-like growth factor 1 (IGF-1), reduced level of, 180
Interferon-γ, *bacillus subtilis* induction of, 198
Interferon-γ production, effects of lactobacilli on, 227
Interspecies differences, 77
Intertrial interval (ITI), 52
Intracellular modulatory pathways, chloride channel and, 183
Ionic conductances during aging, 181

Kidney, rat
blocking of renal thromboxane in, 213
cyclosporin treatment of, 209
Kolmogorov-Smirnov test (SPSS package), 73

Lactate dehydrogenase (LDH) activity, isolated hepatocytes and, 217

Lactobacilli, effects of, on IFN production, 227
Life expectancy, average, 4
Life span
  (−)deprenyl increases, 60, 65
  functional, 5
  modified, 74
  phosponoformic acid and, 195
LINE-1 and *alu* elements in humans, 189
Lipid peroxidation, Alzheimer's dementia and, 338
Lipofuscin
  accumulation of, 36
    in Alzheimer's dementia, 338
  acetyl-L-carnitine reduction of, 158
α-Lipoic Acid, cognition improved by, 122
Lipopolysaccharide (LPS)
  peritoneal cells stimulated by, 199
  spleen cells simulated by, 227
Locomotor activity, phosponoformic acid and, 193
Lou Gehrig's disease, 8

M cells, IFN production and, 203, 229
Major histocompatibility complex (MHC), IFN production and, 204
Malondialdehyde (MDA), Geriforte and, 170
Mathew Scale (MS), 256
Maze
  Morris water (MWM)
    corticosterone treatment and, 81
    L-deprenyl treatment and, 48, 52
    α-lipoic acid treatment and, 123
  radial arm (RAM), corticosterone treatment and, 80–81
  Stone 14-unit T-, 17
Maze models, rat, rationale for, 16
Meclofenoxate (MF), antagonic-stress and, 316, 338
Melatonin, life span prolongation due to, 167–168
Memory dysfunction, rodent models of, 16
Memory quotient (MQ), 336
Memory test, diazepam treatment and, 90
Mental recovery, α-glycerophosphocholine in, 253
2-Mercaptoethylamine (2-MEA)
  free-radical reaction inhibition by, 5
  unpleasant smell of, 166
Metabolism, impaired, aging and, 143
Methocel, α-lipoic acid in, 123
9β-Methylcarbacyclin (9MC), galactosamine-incubated rats and, 216
N-Methyl-D-aspartate (NMDA) receptor, memory acquisition and, 21
Milacemide, memory performance in rats and, 23
Mini Mental State Test (MMST), 256
Mitochondria
  free (nonsynaptic), 155
  rat heart, 234
Mitochondrial DNA (mitDNA)
  acetyl-L-carnitine treatment and, 150
  structural proteins and, 143
Mitochondrial morphology, possible modifications of, 143
Mitochondrial transcript level, 152
Molsidomine, nitric oxide production and, 25
Monoamine oxidase B (MAO-B) activity
  age-dependent increase in, 33
  histochemical demonstration of, 36
  inhibition of, by (−)deprenyl, 66
Motor function
  L-deprenyl treatment and, 47
  diazepam treatment and, 90
  α-lipoic acid treatment and, 126
Mouse
  BALB/c
    Bacillus subtilis spores and, 198
    butylated hydroxytoluene diet of, 7
    lactobacilli treatment of, 226
  BALB/c nude, L-deprenyl treatment of, 72
  BC3F, 2-mercaptoethylamine diet of, 7
  C3H, ethoxyquin diet of, 6
  C57BL
    2-mercaptoethylamine diet of, 7
    butylated hydroxytoluene diet of, 7
  C57BL black, BCE-001 treatment of, 109
  CFLP, BCE-001 treatment of, 106
  LAF_1, 2-mercaptoethylamine diet of, 6
  Mus musculus, BCE-001 treatment of, 109
  NMRI, α-lipoic acid treatment of, 122
  Peromyscus leucopus, BCE-001 treatment of, 109
Multitherapy vs. monotherapy, 338
Muscle
  skeletal, chloride channel conductance of, 180
  vanadyl sulfate treatment of, 174
Muscle fibers, K_{ATP}^+ channels of, 244

Nematoda, genetic and environmental factors affecting, 163
Neoplasms, aging and, 164
Nerve cell membranes, effects of BCE-001 on, 109
Nerve cell metabolism, Hydergine and, 137
Nerve cell profiles, density of, 34
Nerve terminals, Hydergine action at, 137
Neuroimmunocompetence, diazepam treatment and, 89
Neurons, snail, 129

Newton-Gauss nonlinear regression analysis, 74
Nicergoline (NE)
  antagonic-stress and, 315
  antagonic-stress superior to, 332
Nicotinamide adenine dinucleotide phosphate diaphorase (NADPH), 25
Nitric oxide, neurodegeneration and, 24
N^{ω}-Nitro-L-arginine (NARG), inhibition of nitric oxide synthase by, 24
S-Nitroso-*N*-acetylpenicillamine, nitric oxide production and, 25
Nootropic drug, 102, 115
  antagonic-stress and, 316, 332
Noradrenaline (NA), vasoconstrictor responses mediated by, 282
Novelty-induced behavior, L-deprenyl and, 47

OCT, immunohistochemical analysis by, 34
Open field
  habitation in, α-lipoic acid treatment and, 123
  spontaneous activity in, L-deprenyl treatment and, 47
  spontaneous exploration of, diazepam treatment and, 90
Open probability analysis, 246
Oral glucose tolerance test (OGTT), vanadyl sulfate and, 174
Organic mental disorders (OMD), 315
Ovalbumin (OVA), immunization by, 91
Overeating, human, 162
Oxidation, protein, protection against, 117
Oxidative damage, mitDNA transcription and, 159
Oxygen free radicals, BSA exposed to, 115

P-T-Q index, 294
Parkinson's disease, (−)deprenyl and, 60
Peritoneal cells, lipopolysaccharide-stimulated, 199
Peyer's patches, IFN production and, 203, 229
Pharmacological strategies, 16
Phosponoformic acid (PFA), reverse transcriptase experiments and, 190
Phytohemagglutinin (PHA), IFN-γ production and, 198
Pineal gland, bovine, 167
Polyvinylpyrrolidon (PVP), centrophenoxine and BCE-001 dissolved in, 117
Progeroid syndromes, 299
Prostaglandin E_2 (PGE_2), cytoprotective effects of, 216

Rasayans, Geriforte and, 172
Rat
  CFY, BCE-001 treatment of, 106
  CrI:(Wi)BR, α-lipoic acid treatment of, 122
  Fischer-344
    acetyl-L-carnitine treatment of, 151, 234
    BCE-001 treatment of, 109
    corticosterone treatment of, 80
    (−)deprenyl treatment of, 61
    L-deprenyl treatment of, 45–46
    galactosamine treatment of, 222
    Stone maze performance of, 18
  Long Evans, diazepam treatment of, 97
  normotensive, superoxide dismutase–injected, 9
  pinealectomized, 167
  spontaneously hypertensive (SHR), superoxide dismutase-injected, 9
  Sprague-Dawley
    cyclosporine treatment of, 209
    L-deprenyl treatment of, 34
    diazepam treatment of, 97
    galactosamine treatment of, 223
    thromboxane treatment of, 213
    vanadyl sulfate treatment of, 174
  Wistar
    BCE-001 treatment of, 109
    chloride channel conductance and, 181
    diazepam treatment of, 90
    Geriforte treatment of, 170
    9β-methylcarbacyclin treatment of, 216
    prostaglandin E1 treatment of, 216
    TRK-100 treatment of, 216
  Wistar Kyoto, chloride channel conductance and, 181
Receptor-mediated mechanisms, chloride conductance and, 182
Renal function, adverse drug reaction in, 274
Reproductive ability, diazepam treatment and, 91
Respiration, mitochondrial state 3, 241
Reverse transcriptase (RT) inhibitor activity, drugs with, 190

Safe drug, L-deprenyl considered, 72
Sandoz Clinical Assessment-Geriatric (SCAG) scale, 317, 334
Saphenous vein, human, 286–287
Scopolamine hydrochloride (SCOP), impaired memory acquisition and, 20
Self-Assessment Scale-Geriatric (SASG), 320, 335

Senile dementia of the Alzheimer's type (SDAT)
antagonic-stress moderating effect on, 316, 333
superoxide radical in, 9
Serotonin, effect of diazepam treatment on, 95
Serum, laboratory parameters in, 273
Sheep red blood cells (SRBC), immunization by, 91
Snail, pond (*Lymnaea stagnalis L.*), 129
Sodium dodecyl sulfate (SDS), 152
Sodium nitroprusside, nitric oxide production and, 25
Spatial learning, L-deprenyl treatment and, 48, 52
Spatial memory, dog, L-deprenyl treatment and, 54
Spike parameters, 130
Stress, corticosterone treatment and, 84
Striatal dopamine turnover, appearance of, in diazepam-treated rats, 98
Sugar metabolism, vanadyl sulfate and, 174
Sulfide silver staining, density of, 35
Superoxide dismutase (SOD)
(−)deprenyl and, 62
Geriforte evaluated for, 170
Superoxide free radicals (SOR), lipofuscin formation caused by, 170
Survival
BCE-001 treatment and, 110
L-deprenyl treatment and, 46
human, 162
Survival analysis, L-deprenyl and, 73
Synaptic mitochondria, age-related changes in morphology of, 138
Synaptosomal membranes, lipid fluidity in, effects of BCE-001 on, 108
Synaptosomes, isolation of, 151

Teratogenicity, functional, of diazepam, 98
N-Tert-butyl-α-phenylnitrone (PBN), free-radical reaction inhibition by, 4
Tetraiodothyronine (T4), levels of, in Down's syndrome, 301
Thiobarbituric acid reactive substance (TBARS), Geriforte evaluated for, 170
Thromboxane (TXA), renal, blocking of, 213
Thyroid-stimulating hormone (TSH), levels of, in Down's syndrome, 301
Tobacco smoking, human, 162
Tocopherol (vitamin E), antioxidant properties of, 166
Trials to criterion (TTC), 51
Triiodothyronine (T3), levels of, in Down's syndrome, 301
TRK-100, galactosamine-incubated rats and, 216
Tubulointestitial damage, 209
Tumor incidence, constant light regime and, 168

Undereating, phosponoformic acid and, 192

Vanadyl sulfate, beneficial effects of, 174
Vasoconstrictor responses, α-adrenoceptors and, 282
Vasodilators, cerebral, 317, 332
Vitamin E (*see also* Tocopherol), free-radical reaction inhibition by, 5
Wechsler Adult Intelligence Scale (WAIS), 320, 334, 336
Wechsler Memory Scale (WMS), 317, 335–336
World Health Organization (WHO), 271

Zinc deficiency, Down's syndrome subjects and, 300